Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2008-06-24
2008-06-24
Saoud, Christine J (Department: 1647)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S325000, C435S320100, C536S023520
Reexamination Certificate
active
07390638
ABSTRACT:
When interferon gamma (IFNG) is produced in mammalian cell lines a heterogenous population of IFNG polypeptides is obtained due to C-terminal processing of the IFNG polypeptide. Clearly, this constitutes a severe problem in that valuable polypeptide material is lost and, further, it is necessary to carry out time-consuming and cumbersome purification in order to obtain a homogenous population of active IFNG polypeptides having the desired length. It has now been found that an IFNG fragment containing 132 amino acid residues (truncated at the nucleotide level by introducing a stop-codon after the codon encoding amino acid residue no. 132) does not undergo C-terminal truncation or, at least, is not significantly C-terminally truncated. Furthermore, as the IFNG fragment containing 132 amino acid residues is active, this opens up the possibility of producing a homogenous active IFNG polypeptide in eukaryotic host cells, such as CHO cells. More particularly, the present invention relates to an IFNG polypeptide variant exhibiting IFNG activity and having the amino acid sequence shown in SEQ ID NO:12. In a highly preferred embodiment of the invention, the variant comprises at least one further modification, such as 1-10 further modifications, relative to the amino acid sequence shown in SEQ ID NO:12. A particular preferred further modification is E38N+S40T.
REFERENCES:
patent: 4457867 (1984-07-01), Ishida
patent: 4588585 (1986-05-01), Mark et al.
patent: 4604284 (1986-08-01), Kung et al.
patent: 4695623 (1987-09-01), Stabinsky
patent: 4727138 (1988-02-01), Goeddel et al.
patent: 4758656 (1988-07-01), Itoh et al.
patent: 4762791 (1988-08-01), Goeddel et al.
patent: 4832959 (1989-05-01), Engels et al.
patent: 4835256 (1989-05-01), Taniguchi et al.
patent: 4845196 (1989-07-01), Cowling
patent: 4855238 (1989-08-01), Gray et al.
patent: 4897471 (1990-01-01), Stabinsky
patent: 4898931 (1990-02-01), Itoh et al.
patent: 4904584 (1990-02-01), Shaw
patent: 4921698 (1990-05-01), Shirai et al.
patent: 4925793 (1990-05-01), Goeddel et al.
patent: 4929554 (1990-05-01), Goeddel et al.
patent: 4944941 (1990-07-01), Ammann
patent: 4966843 (1990-10-01), McCormick et al.
patent: 4980455 (1990-12-01), Sakaguchi et al.
patent: 5004689 (1991-04-01), Fiers et al.
patent: 5041376 (1991-08-01), Gething et al.
patent: 5096705 (1992-03-01), Goeddel et al.
patent: 5109120 (1992-04-01), Ueno et al.
patent: 5157004 (1992-10-01), Sakaguchi et al.
patent: 5362490 (1994-11-01), Kurimoto et al.
patent: 5376567 (1994-12-01), McCormick et al.
patent: 5382657 (1995-01-01), Karasiewicz et al.
patent: 5518899 (1996-05-01), Kurimoto et al.
patent: 5541293 (1996-07-01), Stabinsky
patent: 5554515 (1996-09-01), Kurimoto et al.
patent: 5574137 (1996-11-01), Gray et al.
patent: 5582824 (1996-12-01), Goeddel et al.
patent: 5595888 (1997-01-01), Gray et al.
patent: 5661009 (1997-08-01), Stabinsky
patent: 5672692 (1997-09-01), Kurimoto et al.
patent: 5690925 (1997-11-01), Gray et al.
patent: 5711944 (1998-01-01), Gilbert et al.
patent: 5723121 (1998-03-01), Takenaga et al.
patent: 5738846 (1998-04-01), Greenwald et al.
patent: 5747646 (1998-05-01), Hakimi et al.
patent: 5770191 (1998-06-01), Johnson et al.
patent: 5792834 (1998-08-01), Hakimi et al.
patent: 6042822 (2000-03-01), Gilbert et al.
patent: 6046034 (2000-04-01), Waschutza et al.
patent: 6120762 (2000-09-01), Johnson et al.
patent: 2 096532 (1992-05-01), None
patent: 077 670 (1983-04-01), None
patent: 088 540 (1983-09-01), None
patent: 089 676 (1983-09-01), None
patent: 098 110 (1984-01-01), None
patent: 110 044 (1984-06-01), None
patent: 146 354 (1985-06-01), None
patent: 158 198 (1985-10-01), None
patent: 170 917 (1986-02-01), None
patent: 219 781 (1987-04-01), None
patent: 229 108 (1987-07-01), None
patent: 256 424 (1987-08-01), None
patent: 236 987 (1987-09-01), None
patent: 237 019 (1987-09-01), None
patent: 306 870 (1989-03-01), None
patent: 121 157 (1989-06-01), None
patent: 145 174 (1989-09-01), None
patent: 370 205 (1990-05-01), None
patent: 446 582 (1991-09-01), None
patent: 546 099 (1994-10-01), None
patent: 795 332 (1997-09-01), None
patent: 593 868 (1998-04-01), None
patent: 860 442 (1998-08-01), None
patent: WO-92/08737 (1991-11-01), None
patent: WO-92/22310 (1992-06-01), None
patent: WO-99/03887 (1998-07-01), None
patent: WO-99/67291 (1999-06-01), None
patent: WO-01/23006 (2000-09-01), None
patent: WO-01/36001 (2000-11-01), None
Wells, Aditivity of Mutational Effects in Proteins, (1990), Biochemistry, vol. 26, No. 37, pp. 8509-8517.
Ngo et al., (1994) The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495.
Arakawa, et al.,Role of Polycationic c-terminal Portion in the Structure and Activity of Recombinant Human Interferon- γ*, The Journal of Biological Chemistry, 261 (18), Jun. 25, pp. 8534-8539 (1986).
Arakawa, et al.,Structure and Activity of Glycosylated Human Interferon-γ, Journal of Interferon Research, 6:687-695 (1986).
Bulleid, et al.,Source of heterogeneity in secreted interferon-γ, Biochem, J. 268:777-781 (1990).
Cantell, et al.,Differential Inactivation of Interferon by a Protease from Human Granulocytes, Journal of Interferon Research 12:177-183 (1992).
Castro, et al.,The macroheterogeneity of recombinant human interferon-γproduced by Chinese-hamster ovary cells is affected by the protein and lipid content of the culture medium, Biotechnol. Appl. Biochem., 21:87-100 (1995).
Curling, et al.,Recombinant human interferon-γ, Differences in glycosylation and proteolytic processing lead to heterogeneity in batch culture, Biochem. J., 272:333-337 (1990).
Devos, et al.,Molecular cloning of human immune interferon cDNA and its expression in eukaryotic cells, Nucleic Acids Research, 10 (8), 2487-2501, Nov. 8, 1982.
Ealick, et al.,Three-Dimensional Structure of Recombinant Human Interferon-γ, Science, 252:698-702 (1991).
Farrar, et al.,The Molecular Cell Biology of Interferon-γand its Receptor, Annu. Rev. Immunol. 11:572-611 (1993).
Gray, et al.,Structure of the human immune interferon gene, Nature, 298:859-863 (Aug. 1992).
Griggs, et al.,The N-terminus and C-Terminus of IFN-γAre Binding Domains for Cloned Soluble IFN-γReceptor, The Journal of Immunology, 149 (2) 517-520 (Jul. 15, 1992).
Gu, et al.,Improvement of Interferon-γSialylation in Chinese Hamster Ovary Cell culture by Feeding of N-Acetylmannosamine, Biotechnology & Bioengineering, 58 (6) 642-648 (1998).
Haelewn, et al.,Interaction of truncated human interferonγvariants with the interferonγreceptor: crucial importance of Arg-129, Biochem. J., 324, 591-595 (1997).
Harmon, et al.,Rapid Monitoring of Site-Specific Glycosylation Microheterogeneity of Recombinant Human Interferon-γ, Anal. Chem., 68 (9) 1465-1473 (1996).
Hogrefe, et al.,Amino Terminus Is Essential to the Structural Integrity of Recombinant Human Interferon-γ, The Journal of Biological Chemistry, 264 (21) 12179-86 (1989).
Hooker, et al.,Constraints on the Transport and Glycosylation of Recombinant IFN-γin Chinese Hamster Ovary and Insect Cells, Biotechnology & Bioengineering, 63 (5) 559-572 (1999).
Hsu, et al.,Structure and activity of Recombinant Human Interferon-γAnalogs, Journal of Interferon Research, 6:663-670 (1986).
James, et al.,N-Glycosylation of Recombinant Human Interferon-γProduced in Different Animal Expression Systems, Bio/Technology, 13:592-96 (Jun. 13, 1995).
Kita, et al.,Characterization of a Polyethylene Glycol Conjugate of Recombinant Human Interferonγ, Drug Design and Delivery, 6:157-167 (1990).
Kontsek, et al.,Engineered Acid-Stable Human Interferon Gamma, Cytokine, 12 (6) 708-710 (Jun. 2000).
Landar, et al.,Design, Characterization, and Structure of a Biologically Active Single-chain Mutant of Human IFN-γ, J. Mol. Biol., 299:169-179 (2000).
Leinikki, et al.,Reduced Receptor Binding by a Human Interferon-γFragment Lacking 11 Carboxyl-Terminal Amino Acids, Journal of Immunology, 139 (10) 3360-3366 (1987).
Littman, et al.,Binding of Unglycosylated and Glycosylated Human R
Andersen Kim Vilbour
Jensen Anne Dam
Nygaard Frank Bech
Van Den Hazel Bart
Fujita Sharion M.
Kruse Norman J.
Maxygen Holdings Ltd.
Pochopien Donald J.
Saoud Christine J
LandOfFree
S99T C-11 Truncated polynucleotides encoding interferon... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with S99T C-11 Truncated polynucleotides encoding interferon..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and S99T C-11 Truncated polynucleotides encoding interferon... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2801318